BerGenBio

Regulatory Filings • May 28, 2024

BerGenBio Announces NCI Clinical Collaboration with UT Health San Antonio and Sobi®

BerGenBio Announces NCI Clinical Collaboration with UT Health San Antonio and Sobi®

Bergen, Norway, May 28, 2024, - BerGenBio ASA (OSE: BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL kinase inhibitors for

severe unmet medical needs, announced today that it has entered into a clinical

trial agreement with the Mays Cancer Center at The University of Texas Health

Science Center at San Antonio (UT Health San Antonio) and Swedish Orphan

Biovitrum AB (Sobi®) (STO:SOBI), a specialized international biopharmaceutical

company.

The parties will collaborate to study BerGenBio's selective AXL inhibitor,

bemcentinib, in combination with Sobi's pacritinib in patients with advanced

lung adenocarcinoma. The clinical study is externally funded and is

complementary to BerGenBio's ongoing Ph1b/2a clinical study in first-line Non

-Small Cell Lung Cancer patients with mutations in the STK11 gene.

Bemcentinib is a first-in-class, selective, oral once-a-day inhibitor of AXL

receptor tyrosine kinase, a promising therapeutic target for serious diseases.

Pacritinib (marketed as VONJO®) is a JAK2 inhibitor indicated for treatment of

myelofibrosis, a bone marrow disorder, and works by blocking certain growth

factors and cytokines.

The clinical study will advance the ground-breaking work of Josephine A.

Taverna, MD, a thoracic oncologist at the Mays Cancer Center and Assistant

Professor in the Division of Hematology and Oncology at UT Health San Antonio.

Dr. Taverna's prior research has demonstrated that AXL and JAK-STAT3 work

together to transmit signals that promote tumor growth and metastasis in

advanced lung cancer. The study will be performed in collaboration with Sobi®

and will be led by Dr. Taverna as the principal investigator and is funded by a

grant received from the National Cancer Institute (NCI) of the National

Institutes of Health (NIH).

Martin Olin, Chief Executive Officer of BerGenBio stated, "We are excited to

work with two stellar partners to bring this intriguing area of research to

patients. This study will further extend our knowledge of the role of selective

AXL inhibition with bemcentinib in lung cancer, our area of highest strategic

focus."

Dr. Taverna commented, "Our data suggests that targeting the AXL-STAT3 pathway

with bemcentinib and pacritinib can prevent tumor cells from recruiting tumor

-associated macrophages and other aggressive host cells into the tumor

microenvironment, disrupting tumor growth and metastatic spread. Understanding

this discovery could shed light on novel therapeutic strategies for lung

cancer."

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Investor Relations / Media Relations

Jan Lilleby

jl@lillebyfrisch.no

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate, bemcentinib, a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and severe respiratory infections. BerGenBio is based in Bergen, Norway with a

subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange

(ticker: BGBIO). For more information, visitwww.bergenbio.com

About Mays Cancer Center at UT Health San Antonio

The Mays Cancer Center at UT Health San Antonio (https://cancer.uthscsa.edu/) is

one of only four National Cancer Institute-designated Cancer Centers in Texas.

The Mays Cancer Center provides leading-edge cancer care, propels innovative

cancer research and educates the next generation of leaders to end cancer in

South Texas. To learn more, visit https://cancer.uthscsa.edu.

Stay connected with the Mays Cancer Center

onFacebook (https://www.facebook.com/UTHealthsaMDAnderson),Twitter (https://twitt

er.com/UTHealthSAMDA),LinkedIn (https://www.linkedin.com/company/uthealthsa),Inst

agram (https://www.instagram.com/uthealthsamdanderson/)andYouTube (https://www.yo

utube.com/@uthealthsamdanderson).

About The University of Texas Health Science Center at San Antonio

The University of Texas Health Science Center at San

Antonio (https://www.uthscsa.edu/) (UT Health San Antonio) is one of the

country's leading health science universities and is designated as a Hispanic

-Serving Institution by the U.S. Department of Education. With missions of

teaching, research, patient care and community engagement, its schools of

medicine, nursing, dentistry, health professions, graduate biomedical sciences

and public health have graduated more than 42,550 alumni who are leading change,

advancing their fields and renewing hope for patients and their families

throughout South Texas and the world. To learn about the many ways "We make

lives better®," visit

UTHealthSA.org (https://uthscsa.edu/?utm_source=uthealthsaorg&utm_medium=pageredi

rect&utm_campaign=uthealthsa).

Stay connected with The University of Texas Health Science Center at San Antonio

onFacebook (https://www.facebook.com/UTHealthSA),Twitter (https://twitter.com/uth

ealthsa),LinkedIn (https://www.linkedin.com/company/uthealthsa),Instagram (https:

//www.instagram.com/uthealthsa/)andYouTube (https://www.youtube.com/uthscsa/).

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties, and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.